Ignite Creation Date:
2024-05-06 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 2:21 PM
Study NCT ID:
NCT05182203
Status:
COMPLETED
Last Update Posted:
2023-02-22
First Post:
2021-12-18
Brief Title:
Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis a Real-life Experience
Sponsor:
Tuen Mun Hospital
Organization:
Tuen Mun Hospital
Study Overview
Official Title:
Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis a Real-life Experience
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record retrospectively These real life data are important as they cannot be provided by randomized controlled trials which are limited by the duration of observation and fixed protocols in research settings Moreover data will represent our local experience of the JAK inhibitors in Chinese patients with RA The retention rate and adverse effects of the JAK inhibitors are compared with conventional TNF inhibitors
Detailed Description:
This study aims to extract data from the Hong Kong Biologics Registry for retention rate of the JAK inhibitors in rheumatoid arthritis and review other adverse events by looking at the medical record retrospectively Efficacy data and adverse events in particular major adverse cardiovascular events MACEs and malignancy will be looked at and compared with the TNF inhibitors Retention withdrawal rates of the drugs will be studied by statistical analyses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None